Lou Gehrig's Disease
9
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (9)
Digital Speech Markers for Monitoring ALS in Spanish Speakers
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
Clinical Trial of High Dose CoQ10 in ALS
Genetics of Familial and Sporadic ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis
A Trial of Tocilizumab in ALS Subjects
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)